Form 4: Recursion Pharmaceuticals CFO Michael Secora Executes Stock Option Plan, Sells Shares

Chief Financial Officer of Recursion Pharmaceuticals, Michael Secora, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Secora, the CFO of Recursion Pharmaceuticals, executed transactions involving Class A Common Stock on September 10 and 11, 2024.
• These transactions involved the exercise of stock options at a price of $2.22 and the subsequent sale of shares at weighted average prices of $6.1666 and $6.3153.
• The transactions were conducted under a 10b5-1 trading plan adopted on March 1, 2024.
• Following these transactions, Secora directly owns 1,402,131 shares of Class A Common Stock and holds options to purchase a significant number of additional shares at various exercise prices and vesting schedules.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and the CFO retains a significant stake in the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
• Secora still holds a significant number of shares and options, indicating continued alignment with the company's success.

Negatives

• The sale of shares by the CFO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Market perception of insider sales, even under a 10b5-1 plan, could create short-term price volatility.
• The vesting schedules of the options could influence future trading activity by the CFO.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical industry, especially for companies like Recursion Pharmaceuticals that are involved in drug discovery and development. Form 4 filings are a routine part of compliance, providing transparency into the transactions of company insiders.

Comparison to Industry Standards

• Monitoring insider transactions is standard practice in the pharmaceutical industry, with companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also subject to similar scrutiny.
• The use of 10b5-1 trading plans is a common strategy among executives to manage their stock holdings while avoiding accusations of insider trading, aligning with practices seen at companies like Pfizer and Johnson & Johnson.
• The vesting schedules and exercise prices of stock options are typical components of executive compensation packages in the biotech sector, comparable to those offered by companies like Moderna and BioNTech.

Stakeholder Impact

• Shareholders may react to the news of insider sales, although the pre-planned nature of the transactions should mitigate concerns.
• Employees may view the transactions as a standard part of executive compensation.

Key Dates